Clinical Trial Update: Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEs [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating escalating doses of MS1819-SD added to a stable dose of PPEs in cystic fibrosis patients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Cystic Fibrosis Gastrointestinal Disease
• Cystic Fibrosis of Pancreas

Drugs mentioned

• MS1819-SD (MS1819-SD)
• PPEs

Snippet

Sponsor: AzurRx SAS | Conditions: Cystic Fibrosis, Cystic Fibrosis Gastrointestinal Disease | Phase 2 | Status: COMPLETED